Exelixis Inc. (NASDAQ: EXEL) announced that its partner Ipsen received European Commission approval for CABOMETYX (cabozantinib) to treat adult patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE